ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1870

Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody Positive Dermatomyositis

Richard Seto1, Sangmee Bae1 and Christina Charles-Schoeman2, 1University of California Los Angeles, Los Angeles, CA, 2Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

Meeting: ACR Convergence 2022

Keywords: COVID-19, dermatomyositis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with dermatomyositis (DM) and antibodies (ab) to melanoma differentiation associated gene 5 (MDA5) share similar clinical characteristics to patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including high risk of fatal, rapidly progressive interstitial lung disease (RP-ILD). Nearly 50% of patients with COVID 19 have anti-MDA5 ab, which are associated with worse outcomes (Front Immunol 2021 Dec 20;12:791348). Shared pathogenic pathways between MDA5 ab positive DM and COVID 19 have been proposed. The current work evaluated the clinical outcomes of anti-MDA5 positive DM patients following infection or vaccination for SARS-CoV-2.

Methods: A retrospective chart review of a large longitudinal idiopathic inflammatory myopathies (IIM) patient cohort at a single academic center was done to identify DM patients with anti-MDA5 ab. Chart review for a comparison cohort of DM patients with antibodies to TIF1 gamma was performed. Clinical variables collected from chart review included demographic information, SARS-CoV-2 vaccination status, type of vaccine used, dates of vaccinations, vaccine reactions, SARS-CoV-2 infection status, and medication use including changes in immunosuppressive agents at time of SARS-CoV-2 infection or vaccination.

Results: A total of 25 anti-MDA5 ab+ DM patients with ongoing follow-up appointments during the Covid pandemic were identified in the cohort, including 24 patients with data on SARS-CoV-2 infection and vaccination available for review (Age = 51 ± 15,70%F). 20 DM patients with TIF1 gamma ab were identified with active follow-up including 17 patients with SARS-CoV-2 data for review (Age= 46 ± 15, 94%F). 23/25 MDA5 ab positive patients and 17/17 TIF1 gamma ab positive patients received vaccination for SARS-CoV-2. Adverse reactions associated with vaccination were generally minor and of short duration. One patient in the TIF1 gamma ab group had a DM disease flare with vaccination requiring increase in steroid dose. The most common adverse events with vaccination across both DM groups included injection site soreness (44%) followed by fatigue/malaise (24%), upper respiratory symptoms (5%), headache (5%,) fever (5%), and rash (2%). Symptoms generally lasted 1-3 days and resolved without intervention. No differences in these adverse events were noted between MDA5 and TIF1 gamma ab positive groups (p >0.05 for Chi Square/Fisher’s exact test). 8 MDA5 ab positive patients including one patient without vaccination had Covid 19. None of these patients were hospitalized or had disease flares associated with Covid 19 and all had mild symptoms with full recovery. No documented Covid 19 occurred in the TIF1 gamma ab group.

Conclusion: Vaccination againstSARS-CoV-2 was generally well tolerated in a cohort of patients with anti-MDA5 antibody positive DM. Adverse reactions to vaccination were similar to those reported in the general population (JAMANetw Open.2021;4(12)) and a comparison anti-TIF1 gamma antibody positive DM cohort. No hospitalizations for Covid 19 or disease flares occurred in 8 MDA5 ab positive patients infected with SARS-CoV-2.


Disclosures: R. Seto, None; S. Bae, None; C. Charles-Schoeman, AbbVie, Bristol Myers Squibb (BMS), Pfizer, Regeneron-Sanofi, Gilead.

To cite this abstract in AMA style:

Seto R, Bae S, Charles-Schoeman C. Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody Positive Dermatomyositis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/clinical-outcomes-following-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-infection-and-vaccination-in-patients-with-anti-melanoma-differentiation-associated-gene-5-mda5-antibody-posi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-following-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-infection-and-vaccination-in-patients-with-anti-melanoma-differentiation-associated-gene-5-mda5-antibody-posi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology